NOVO-OXCARBAZEPINE 600 MG — DIN 02312042
OXCARBAZEPINE : 600 MG · NOVOPHARM LIMITED · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is NOVO-OXCARBAZEPINE?
NOVO-OXCARBAZEPINE 600 MG contains OXCARBAZEPINE : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02312042, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 24-Jul-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Oxcarbazepine cost around the world?
Oxcarbazepine is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 65 | USD███.██ |
| Saudi Arabia | public | 7 | 11 | SAR███.██ |
| Australia | ex-manufacturer | 1 | 8 | AUD███.██ |
| South Africa | single exit price | 5 | 6 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 4 | BHD███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
108 pack listings across 31 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Oxcarbazepine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Oxcarbazepine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Oxcarbazepine, across 22 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 6 | 3 | JAMP OXCARBAZEPINE, JAMP-OXCARBAZEPINE | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 4 | 3 | TRILEPTAL 150 MG, TRILEPTAL 300 MG, TRILEPTAL 600 MG, TRILEPTAL ORAL SUSPENSION | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-OXCARBAZEPINE | Sourceable in Canada |
| JUBILANT GENERICS LIMITED | 3 | 0 | OXCARBAZEPINE | No marketed DIN |
| NOVOPHARM LIMITED | 3 | 0 | NOVO-OXCARBAZEPINE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ OXCARBAZEPINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 600 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Oxcarbazepine |
|---|---|
| ATC code | N03AF02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02312042 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2312042 |
| Brand name | NOVO-OXCARBAZEPINE |
| Generic / active ingredient | OXCARBAZEPINE : 600 MG |
| Market authorization holder | NOVOPHARM LIMITED |
| Health Canada schedule | Prescription |
| ATC code | N03AF02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N03AF |
| Current status | CANCELLED PRE MARKET |
| Status date | 24-Jul-2018 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXCARBAZEPINE | 300 MG | TABLET | APOTEX INC | MARKETED | 02284308 |
| APO-OXCARBAZEPINE | 600 MG | TABLET | APOTEX INC | MARKETED | 02284316 |
| APO-OXCARBAZEPINE | 150 MG | TABLET | APOTEX INC | MARKETED | 02284294 |
| JAMP OXCARBAZEPINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02560593 |
| JAMP OXCARBAZEPINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02560607 |
| JAMP OXCARBAZEPINE | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02560615 |
| TRILEPTAL 300 MG | 300 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02242068 |
| TRILEPTAL 600 MG | 600 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02242069 |
| TRILEPTAL ORAL SUSPENSION | 60 MG | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02244673 |
| JAMP-OXCARBAZEPINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | 02440725 |
2 · Same class — other molecules in ATC N03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Carbamazepine | APO-CARBAMAZEPINE · APO-CARBAMAZEPINE CR · BIO-CARBAMAZEPINE · CARBAMAZEPINE 200 TAB 200MG · +26 more | 46 | 11 | Yes |
| Oxcarbazepine | APO-OXCARBAZEPINE · JAMP OXCARBAZEPINE · JAMP-OXCARBAZEPINE · NOVO-OXCARBAZEPINE · +6 more | 22 | 9 | Yes |
| Eslicarbazepine | APO-ESLICARBAZEPINE · APTIOM · AURO-ESLICARBAZEPINE | 12 | 8 | Yes |
| Rufinamide | AURO-RUFINAMIDE · BANZEL | 6 | 5 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N03AX | Brivaracetam · Cannabidiol · Cenobamate · Lacosamide · Lamotrigine · +4 more | 391 | 197 |
| N03AG | Valproic Acid · Vigabatrin | 75 | 19 |
| N03AA | Phenobarbital · Primidone | 39 | 13 |
| N03AB | Fosphenytoin · Phenytoin · Phenytoin, Combinations | 17 | 8 |
| N03AE | Clonazepam | 55 | 8 |
| N03AD | Ethosuximide · Mesuximide | 5 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NOVO-OXCARBAZEPINE called?
The same molecule, Oxcarbazepine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Trileptal | Latin | Australia, Bahrain, Morocco |
| Trileptal Fct | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.